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Abstract
Oral tolerance is classically deﬁned as the suppression of immune responses to antigens (Ag) that have been administered
previously by the oral route. Multiple mechanisms of tolerance are induced by oral Ag. Low doses favor active suppression,
whereas higher doses favor clonal anergy/deletion. Oral Ag induces Th2 (IL-4/IL-10) and Th3 (TGF-b) regulatory T cells
(Tregs) plus CD4þCD25þ regulatory cells and LAPþT cells. Induction of oral tolerance is enhanced by IL-4, IL-10,
anti-IL-12, TGF-b, cholera toxin B subunit (CTB), Flt-3 ligand, anti-CD40 ligand and continuous feeding of Ag. In
addition to oral tolerance, nasal tolerance has also been shown to be effective in suppressing inﬂammatory conditions with
the advantage of a lower dose requirement. Oral and nasal tolerance suppress several animal models of autoimmune
diseases including experimental allergic encephalomyelitis (EAE), uveitis, thyroiditis, myasthenia, arthritis and diabetes in
the nonobese diabetic (NOD) mouse, plus non-autoimmune diseases such as asthma, atherosclerosis, colitis and stroke.
Oral tolerance has been tested in human autoimmune diseases including MS, arthritis, uveitis and diabetes and in allergy,
contact sensitivity to DNCB, nickel allergy. Positive results have been observed in phase II trials and new trials for arthritis,
MS and diabetes are underway. Mucosal tolerance is an attractive approach for treatment of autoimmune and
inﬂammatory diseases because of lack of toxicity, ease of administration over time and Ag-speciﬁc mechanism of action.
The successful application of oral tolerance for the treatment of human diseases will depend on dose, developing immune
markers to assess immunologic effects, route (nasal versus oral), formulation, mucosal adjuvants, combination therapy and
early therapy.
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Autoimmunity and oral tolerance
“Immunological tolerance” has often been deﬁned as
a mechanism by which the immune system prevents
pathologic autoreactivity against self and thus pre-
vents autoimmune diseases. This deﬁnition of
tolerance as a negative counterpart of immunity
comes from the classical work of Burnet who ﬁrst
proposed self/non-self discrimination as a major
principle driving the operation of the immune system
and tolerance to self-components as a deletional event
taking place at early periods of development (Burnet
1959). According to Burnet’s “Clonal Selection
Theory”, self tolerance was based on the blindness
of the mature immune system to body components.
The description of the thymic selection of T
lymphocytes, of the subsets of T cells and their
distinct actions, as well as the demonstration of auto-
reactive B and T cells in normal individuals
contributed to change this scenario (Avrameas 1991;
Kerlero de Rosbo et al. 1993; Zhang et al. 1994;
Lacroix-Desmazes et al. 1998). It became clear to
several researchers that natural tolerance to auto-
components is a more complex phenomenon. Phys-
iological autoimmunity, as a self-assertion process that
generates immune regulation and pathological auto-
immunity has to be distinguished as different out-
comes of self-recognition (Cohen and Young 1991;
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approach clearly demonstrated that natural tolerance
to self is an active process that depends on the activity
of non-inﬂammatory/regulatory auto-reactive T lym-
phocytes present at a stable frequency in the normal
repertoire (Cohen and Young 1991; Modigliani et al.
1996; Sakaguchi 2004).
In analogy to the natural non-inﬂammatory
reactivity that the immune system mounts to self
components, the name “oral tolerance” has been given
in the seventies (Vaz et al. 1977) to the immunological
tolerance to antigens (Ag) that access the body via the
oral route. Oral tolerance has been classically deﬁned
as the speciﬁc suppression of cellular and/or humoral
immune responses to an Ag by prior administration of
the Ag by the oral route. Since most of the natural
contact with foreign Ag occurs via the mucosal
surfaces, tolerance induction to commensal bacteria
and dietary proteins represents the major immuno-
logical event taking place in the gut in physiological
conditions.
Oral tolerance is of unique immunologic import-
ance since it is a continuous natural immunologic
event driven by exogenous Ag. Due to their privileged
access to the internal milieu, commensal bacteria and
dietary Ag that continuously contact the mucosa
represent a frontier between foreign and self-com-
ponents. Thus, oral tolerance is a form of peripheral
tolerance that evolved to treat external agents that gain
access to the body via a natural route as internal
components that then become part of self.
Within the view of self tolerance as an active
process, auto-immune diseases would arise from
defects in immunoregulatory processes. The usual
therapies for these pathological conditions rely on
non-speciﬁc immunossupression with several undesir-
able side effects. Since oral tolerance is such a potent
way of inducing regulatory cells towards speciﬁc Ag,
the idea of using the oral route to trigger tolerance to
Ag involved in autoimmune diseases comes as an
important clinical application of the phenomenon.
Although the idea was already present as a theoretical
possibility in the seventies, it was only successfully
tested in the classical studies of four groups of
researchers working on experimental models of
arthritis (Nagler-Anderson et al. 1986; Thompson
and Staines 1986) and multiple sclerosis (Bitar and
Whitacre 1988; Higgins and Weiner 1988) in the
eighties.
Mechanisms of oral tolerance induction
A concept has arisen in oral tolerance studies that
there are two primary effector mechanisms of oral
tolerance: low doses of Ag favor the generation of
regulatory cell-driven tolerance whereas high doses of
Ag favor either clonal deletion (Chen et al. 1995;
Marth et al. 1996; Meyer et al. 2001) or anergy of
speciﬁc T cells (Mowat et al. 1982; Whitacre et al.
1991; Melamed and Friedman 1993; Friedman and
Weiner 1994; Inada et al. 1997). Low doses of Ag
would preferentially induce regulatory T cells (Tregs)
that secrete down-modulatory cytokines such as
TGF-b, IL-10 and IL-4 (Miller et al. 1992). TGF-b
secreting CD4
þ and CD8
þT cells have been isolated
and cloned from the PP and MLN of orally tolerized
mice (Chen et al. 1994, 1996; Santos et al. 1994;
Wang et al. 1994) and from the peripheral blood of
humans fed MBP (Fukaura et al. 1996). T cells cloned
from tolerized mice have been ascribed to a unique
subset of CD4
þT cell, the Th3 cell (Chen et al. 1994;
Fukaura et al. 1996; Faria and Weiner 2005). This
population appears to be dependent on IL-4, rather
than IL-2 for its growth and some Th3 clones produce
IL-4 and/or IL-10 together with TGF-b (Chen et al.
1994; Faria and Weiner 2005). In addition, in TCR
transgenic mice, oral adminstration of Ag also resulted
in a relative increase of CD4þCD25þ Tregs
expressing either CTLA-4 (Zhang et al. 2001) or
FoxP3 (Mucida et al. 2005). These cells have
suppressive properties in vitro and can transfer
tolerance to naive recipients (Zhang et al. 2001;
Nagatani et al. 2004). They either secrete high levels
of IL-10 and TGF-b (Zhang et al. 2001) or are
dependent in TGF-b for their development (Mucida
et al. 2005). In addition to the secreted form of TGF-
b, murine CD4þCD25þ or CD4þCD25 2 regu-
latory cells have been reported to express latency-
associated peptide (LAP) and TGF-b on the surface
after activation and exert regulatory function by the
membrane-bound TGF-b in vitro (Nakamura et al.
2001; Oida et al. 2003). Recombinant latency-
associated peptide (rLAP) was also shown to reverse
suppression by mouse CD4þCD25þ T cells as well
as their human counterparts, CD4þCD25
high T cells
(Nakamura et al. 2004). Thus, surface expression of
the latent form of TGF-b can be another mode of
action for TGF-b.
The generation of Ag-speciﬁc regulatory cells seem
to be a result of Ag presentation by gut-associated
Antigen-presenting cells (APC) (Viney et al. 1998;
Simioni et al. 2004) that are particularly involved in
the induction of TGF-b-producing T cells (Simioni
et al. 2004). These Ag-speciﬁc regulatory cells migrate
to lymphoid organs suppressing immune responses by
inhibiting the generation of effector cells and to target
organs, suppressing disease by releasing Ag-non
speciﬁc cytokines (bystander suppression).
Since these pioneer studies, evidence has been
reported that the two forms of tolerance are not
mutually exclusive and they may overlap. Recent
studies on the properties of Tregs also describe
them as “anergic” (Takahashi et al. 1998; Taams et al.
2002; Sakaguchi 2004) and deletional events
taken place in the gut mucosa (Ramachandran et al.
2000) result local TGF-b secretion by macrophages
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2001). This cytokine acts as a growth factor for the
generation of Th3 cells (Paul and Seder 1994; Weiner
2001; Faria and Weiner 2005) and of CD4þFoxP3þ
Tregs (Chen et al. 2003; Horwitz et al. 2003;
Sakaguchi 2004). Thus, anergy/deletion and active
regulation may be different aspects of the same
tolerogenic processes that are triggered by antigenic
contacts in the intestine.
Major issues involved in the use of oral tolerance
as a therapy
Oral tolerance has been already successfully tested in a
number of experimental models for autoimmune
diseases as well as other inﬂammatory conditions such
as allergy and transplantation (Faria and Weiner
2005). After this intensive research work, three major
issues emerged on the therapeutic use of oral tolerance
for autoimmune diseases: (1) the choice of a target Ag;
(2) the limiting therapeutic situation of treating
already sensitized subjects; and (3) the large doses
that are sometimes required for its efﬁcient induction.
First, the rationale for the use of oral tolerance as a
therapeutic tool in autoimmune conditions is mainly
that it would provide a type of speciﬁc suppression
avoiding the side effects of non-speciﬁc immunosu-
pression. One potential problem in its use is the choice
of the target Ag. It is not always clear which are the
autoantigens involved in autoimmune pathogenesis.
Fortunately, as we will discuss below, oral tolerance is
associated with a bystander suppression event that
spreads the regulatory activity triggered by oral
tolerance to other Ag presented in the same context.
Cross-suppression (Vaz et al. 1981) or bystander
suppression (Miller et al. 1991) of a non-related
inﬂammatory event by mucosally administered Ag is
now a well described phenomenon that provides a way
to circumvent the need of unique target for oral
tolerance induction.
Second, it has been already reported that oral
tolerance is easily induced in naı ¨ve animals but primed
animals are more resistant to its suppressive effects
(Yoshino et al. 1995; Conde et al. 1998; Faria and
Weiner 2005). Indeed, immunized mice are suscep-
tible to oral tolerance induction when the Ag is
administered up to 7 days after immunization. Then,
they become progressively resistant to tolerance
induction and 14 days later they are completely
refractory (Conde et al. 1998). As a way to circumvent
this problem, there are a number of adjuvants and
regimens of feeding already described that modulate
positively the mechanisms involved in oral tolerance
i n d u c t i o n( s e es e c t i o no nm o d u l a t i o no fo r a l
tolerance).
Third, to achieve effective suppression with the oral
tolerance regimen, sometimes large doses of Ag are
necessary. This requirement may hinder the use of
oral tolerance to human subjects. As we will discuss
below, nasal tolerance may be an alternative in many
cases since the nasal mucosa is also an effective route
to induce suppression and the doses required are
usually 10-fold lower.
Bystander suppression (Table I)
Bystander suppression is a concept that regulatory
cells induced by a fed Ag can suppress immune
responses stimulated by different Ag, as long as the fed
Ag is present in the anatomic vicinity (Faria and
Weiner 2005). It was described during an investigation
of the regulatory cells induced by oral administration
of low doses of MBP (Miller et al. 1991). It solves a
major conceptual problem in the design of Ag- or
T-cell-speciﬁc therapy for inﬂammatory autoimmune
diseases such as MS, type 1-diabetes and rheumatoid
arthritis (RA) in which the autoantigen is unknown or
where there are reactivities to multiple autoantigens
in the target tissue. During the course of chronic
inﬂammatory autoimmune processes in animals,
there is intra- and interantigenic spread of auto-
reactivity at the target organ (Lehmann et al. 1992;
Cross et al. 1993; Tisch et al. 1993). Similarly in
human autoimmune diseases, there are reactivities to
Table I. Models of autoimmune and other diseases that demonstrate bystander suppression.
Disease Immunizing Ag Oral Ag Target organ
Arthritis BSA, mycobacteria CII Joint
EAE PLP MBP Brain
EAE MBP peptide 71–90 MBP peptide 21–40 Brain
EAE MBP OVA Lymph node, DTH response
Diabetes LCMV Insulin Pancreatic islets
IBD CD4 þ CD45RB
high T cell transfer OVA Intestine
Stroke None MBP, MOG Brain
Nerve injury None MBP Brain
Atherosclerosis None Hsp65 Aortic arch
Abbreviation: BSA, bovine serum albumin; DTH, delayed-type hypersensitivity; EAE, experimental allergic encephalomyelitis; LCMV,
lymphocytic choriomeningitis virus; MBP, myeline basic protein, OVA, ovalbumin; PLP, proteolipid; and IBD, inﬂammatory bowl disease.
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example, in MS, there is immune reactivity to at
least three myelin Ag: MBP, proteolipid protein (PLP)
and myelin oligodendrocyte glycoprotein (MOG)
(Kerlero de Rosbo et al. 1993; Zhang et al. 1994).
In type 1 diabetes, there are multiple islet-cell Ag
that could be the target of autoreactivity including
glutamic acid decarboxylase (GAD), insulin and
heat shock proteins (HSP) (Harrison 1992). Because
regulatory cells induced by oral Ag secrete non-
speciﬁc cytokines after being triggered by the fed Ag,
they suppress inﬂammation in the microenvironment
where the fed Ag is localized. Thus, for a human
organ-speciﬁc inﬂammatory disease, it is not necess-
ary to know the speciﬁc Ag that is the target of an
autoimmune response, but only to feed an Ag capable
of inducing regulatory cells, which then migrate to the
target tissue and suppress inﬂammation.
The mechanisms by which this process could occur
are usually assumed to reﬂect the production of
inhibitory cytokines by the tolerized Treg, with
resulting suppression of the T cells with other
speciﬁcities in the vicinity. IL-10 and TGF b are the
most favored cytokines in this respect. This idea is
supported by several studies that showed TGF-b-
dependent suppression in experimental allergic ence-
phalomyelitis (EAE) studies using different myelin Ag
(Miller et al. 1991, 1993). On the other hand, the role
of IL-10 in the phenomenon is supported by the
ﬁndings that OVA-speciﬁc Tr1 cells can prevent IBD
(induced by gut bacteria), providing OVA is present in
the intestinal environment (Groux et al. 1997).
Inhibitory mediators or molecules on the surface of
Tregs could act directly on the responding T cells or
they could act by “deactivating” the APC which is
attempting to stimulate the third party T cell. Ag-
presenting dendritic cells (DCs) can act as “temporal
bridges” to relay information from orally tolerized
memory T cells to naive CD4 þ T cells (Lanzavec-
chia 1998). Since APC, specially Dcs, recirculate, this
idea is consistent with all the data available on the
phenomenon including reports showing that a type of
bystander suppression occurs with Ag at different
anatomic sites or injected days apart from each other
(Carvalho et al. 1994, 1997).
Bystander suppression has been demonstrated in a
number of autoimmune disease models. For instance,
PLP-induced EAE can be suppressed by feeding MBP
(al-Sabbagh et al. 1994) or by administering TGF-b-
secreting MBP-speciﬁc T-cell clones from orally
tolerized animals (Chen et al. 1994). In the Lewis
rat model of EAE, disease induced by MBP peptide
71–90 can be suppressed by feeding peptide 21–40
(Miller et al. 1993). In arthritis models, adjuvant- and
Ag-induced arthritis can be suppressed by feeding
type II collagen (CII) (Yoshino et al. 1995). In a virus-
induced model of diabetes, whereby a lymphocytic
choriomeningitis virus (LCMV) protein is expressed
on the insulin promoter and the animal is then
infected with the LCMV, diabetes can be suppressed
by feeding insulin (von Herrath et al. 1996).
In theory, bystander suppression could be applied
for the treatment of organ-speciﬁc inﬂammatory
conditions that are not classic autoimmune diseases,
such as psoriasis, or could be used to target anti-
inﬂammatory cytokines to an organ where inﬂam-
mation may play a role in disease pathogenesis even if
the disease is not primarily inﬂammatory in nature.
For example, oral MBP decreased stroke size in a rat
stroke model, presumably by decreasing inﬂammation
associated with ischaemic injury (Becker et al. 1997).
Induction of nasal tolerance in mice to a peptide of
the myelin Ag MOG also reduces ischemic injury
following stroke. Regulatory cells are generated in
tolerant wild type but not in IL-10-deﬁcient mice.
Moreover, IL-10-producing MOG speciﬁc CD4þ
T cells can transfer tolerance to naı ¨ve recipients
(Frenkel et al. 2003, 2005). Bystander suppression
achieved by oral Ag in non-immune pathological
conditions may mimic a physiological protective
reaction to self Ag in response to inﬂammatory insult
as observed in the experimental model of central
nervous system (CNS) axonal injury in EAE-
susceptible and resistant rat strains. Oral treatment
with low-dose MBP is beneﬁcial for post-traumatic
survival of retinal ganglion cells in Lewis rats following
optic nerve injury (Monsonego et al. 1996). HSP,
known to be up-regulated in inﬂammatory situations,
are also a suitable target for bystander suppression
strategies. Oral as well as nasal administration of
hsp65 in LDL-R deﬁcient mice fed a high colesterol
diet downmodulates IL-2 and IFN-g production and
aortic plaque development. Production of IL-10 but
not TGF-b is up-regulated in hsp-tolerized mice
(Harats et al. 2002; Maron et al. 2002a).
Modulation of oral tolerance (Table II)
Data on animal models showed also that a number of
factors have been reported to modulate oral tolerance.
As oral tolerance has usually been deﬁned in terms of
Th1 responses, anything that suppress Th1 and/or
enhances Th2 or Th3 cell development would
enhance oral tolerance. Th3 cells appear to use IL-4
and TGF-b itself as one of its growth/differentiation
factors. Thus, IL-4 administration i.p., oral IL-10 and
IL-4 can also enhance oral tolerance when co-
administered with Ag and cytokines have also been
administered by the nasal route (Inobe et al. 1998;
Slavin et al. 2001). Oral but not subcutaneous
lipopolysaccaride (LPS) enhances oral tolerance to
MBP and is associated with increased expression of
IL-4 in the brain (Khoury et al. 1992). In the uveitis
model, intraperitoneal IL-2 potentiates oral tolerance
and is associated with increased production of TGF-
b, IL-10 and IL-4 (Rizzo et al. 1994). Oral Ag delivery
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2002; Pecquet et al. 2000) or liposomes (Masuda et al.
2002) or poly-lactic-co-pucolic acid (PLGA) (Kim
et al. 2002) also enhances oral tolerance. In the
arthritis model, administration of TGF-b or dimaprid
(a histamine type 2 receptor agonist) i.p., both of
which are believed to promote the development
of immunoregulatory cells, enhances the induction
of oral tolerance to collagen II even after the onset
of arthritis (Thorbecke et al. 1999). Coupling Ag to
recombinant cholera toxin B subunit (CTB) enhances
their ability to induce peripheral immune tolerance
(Holmgren et al. 2003). A recently reported vaccine
consisting of a fusion protein composed of CTB
subunit and insulin produced in the hemolymph of
silkworm showed ability to enhance oral tolerance
induction in non-obese diabetic mice (Gong et al.
2005). On the other hand, cholera toxin (CT) is one of
the most potent mucosal adjuvants and feeding CT
abrogates oral tolerance when fed with an unrelated
protein Ag. Large doses of IFN-g given intraperito-
neally abrogate oral tolerance (Zhang et al. 1990a),
anti-IL-12 enhances oral tolerance and is associated
both with increased TGF-b production and T cell
apoptosis (Marth et al. 1996) and subcutaneous
administration of IL-12 reverses mucosal tolerance
(Eaton et al. 2003). Oral IFN-b and IFN-t (tau)
synergizes with the induction of oral tolerance in
SJL/PLJ mice fed low doses of MBP (Nelson et al.
1996; Soos et al. 2002). Other exogenous agents
which have been reported to enhance oral tolerance
when given orally include parasite Ag from
H. polygyrus (Shi et al. 2000), polysaccharide AZ9
from Klebsiella oxitoca (Sugihara et al. 2002) and
Schistosoma Mansoni egg antigens (SEA) (Maron et al.
1998). Antibody (Ab) to chemokine monocyte
chemotactic protein 1 (MCP-1) abrogates oral toleran
(Karpuset al. 1996). Intraperitoneal co-adminstration
of normal IgG to mice orally treated with Ag leads to
a sustained and intense immunological tolerance
including those of lupus-prone NZB X NZW lineage
(Mengel et al. 2005). We also found recently that not
only agents but certain regimens of feeding interfere
with oral tolerance induction. Continuous and serial
feeding regimens of the Ag administration enhances
signiﬁcantly oral tolerance by up-regulating IL-10 and
TGF-b (Faria et al. 2003).
Nasal tolerance (Table III)
In the nasal and upper respiratory tract of human and
animals, there is an intact mucosal lymphoid tissue
containing two structures: nasal associated lymphoid
tissue (NALT) and the bronchus associated lymphoid
tissue (BALT). In rodents, there is a lymphoid tissue
that surrounds the nasal cavity whereas in humans
and certain other species, there is an orophariyngeal
lymphoid tissue (Waldeyer’s ring) that includes the
adenoid and the bilateral tubule, palatine and lingual
tonsils (Goeringer and Vidic 1987). The bronchial
mucosas resemble the gut mucosa with a network
of Dcs and lymphocytes scattered in the airway
epithelium. One relevant difference between the
absorption of Ag in the upper respiratory tract and
in the gut is the absence of digestion in the former.
This feature may explain why minute doses of Ag are
effective in inducing tolerance via the nasal route as
compared to the high doses usually required for oral
administration.
Nasal adminstration of Ag has been shown to
suppress a number of experimental autoimmune
diseases including diabetes in nonobese diabetic
(NOD) mice (Daniel and Wegman 1996; Harrison
et al. 1996; Tian et al. 1996), pristane- and collagen-
induced arthritis (Staines et al. 1996; Myers et al.
1997; Garcia et al. 1999; Lu and Holmdahl 1999),
EAE in mice (Metzler and Wraith 1993; Liu et al.
1998) and rats (Bai et al. 1997; Li et al. 1998),
experimentalautoimmunemyastheniagravis(EAMG)
(Ma et al. 1995; Shi et al. 1999), experimental
Table II. Modulation of oral tolerance
Enhances Prevents
IL-2 IFN-g
IL-4, IL-10 IL-12, IL-18
Helminth Ag CD80 over-expression
Anti-CD4 Anti-TGF-b Ab
Anti-IL-12 CT
CTB Anti-MCP-1 (CCL2)
LPS IBD
Flt3L Anti-gd Ab
Type 1 IFN (b and t) GVHR
Multiple emulsions CY, 20-dGuo
Lipossomes Oestradiol
PLGA
Continuous feeding
TGF-b
Pooled IgG
Abbreviations: CT, cholera toxin; CTB, cholera toxin B subunit;
IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; MCP,
monocyte chemotactic protein 1; GVHR, Graft-versus-Host
Reaction; CY, cyclophosphamide; 20-dGuo, 20-deoxyguanosine;
TGFb, transforming growth factor? b; and PLGA, poly lactic-co-
pucolic acid.
Table III. Autoimmune and inﬂammatory disease models sup-
pressed by nasal tolerance.
Model Administered protein
EAE MBP, MBP peptides
EAMG AChR
EAU Retinal Ag
Diabetes Insulin, GAD65
EAN Myelin peptide
Arthritis Hsp65, collagen II and IX, CII peptide
Atherosclerosis Hsp65
Stroke MOG peptide
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experimental autoimmune neuritis (EAN) (Zhu et al.
1998).
The mechanisms involved in the inhibition of
disease development after nasal administration of
Ag involve induction of CD4þT cell unresponsive-
ness or Treg development (Harrison et al. 1996;
Shi et al. 1999; Akbari et al. 2001; Samsom et al.
2004). These Tregs are described as gb CD8þ T cells
(Harrison et al. 1996) or ab CD4þT cells that secrete
high amounts of IL-10 (Akbari et al. 2001; Samsom
et al. 2004). Akbari et al. (2001) suggest that
IL-10-producing DCs from the lungs are particularly
effective in inducing the development of Tr1 cells
(CD4þ cells that produce IL-10) upon nasal adminis-
tration of Ag. Some authors also found nasal tolerance
to be associated with the induction of TGF-b-
producing T cells (Shi et al. 1999; Ostroukhova et al.
2004). Interestingly, bystander suppression in experi-
mental models of atherosclerosis (Maron et al.
2002a,b) and stroke (Frenkel et al. 2003, 2005) is
effectively induced by nasal administration of Ag and
suppression it is mediated by IL-10-producing T cells.
Therapeutic applications of oral tolerance in
autoimmune and inﬂammatory diseases in
animals (Table IV)
Several studies have demonstrated the effectiveness of
oral administered autoantigens in animal models of
autoimmune and inﬂammatory diseases (Faria and
Weiner 2005).
Experimental allergic encephalomyelitis
The ﬁrst studies to show that orally administered
myelin Ag could suppress EAE were performed in the
Lewis rat. EAE was suppressed by low doses of oral
MBP and MBP fragments (Higgins and Weiner 1988)
and by high doses of MBP given in bicarbonate
(Bitar and Whitacre 1988). High doses of MBP can
suppress EAE via the mechanism of T cell clonal
anergy (Javed et al. 1995) whereas multiple lower
doses prevent EAE by transferable active cellular
suppression (Miller et al. 1993). In the nervous system
of low-dose-fed animals, inﬂammatory cytokines such
as TNF and IFN-g are down-regulated and TGF-b is
up-regulated (Khoury et al. 1992). Administration of
myelin to sensitized animals in the chronic guinea pig
model or larger doses of MBP in the murine EAE
model is protective and does not exacerbate disease
(Brod et al. 1991; Meyer et al. 1996) and long term
(6 month) administration of myelin in the chronic
EAE modelwas beneﬁcial (al-Sabbagh et al. 1996a,b).
A number of studies have demonstrated suppres-
sion of EAE in murine models. Both conventional and
T cell receptor transgenic animals have been used and
both oral MBP and oral PLP have been administered
although the majority of studies have used MBP.
In these models, MBP regulatory clones have been
described and such cells have also been induced in
MBP T cell receptor transgenic mice. Both CD4 and
CD8 cells have been shown to mediate active
suppression and anergy/deletion have also been
demonstrated in oral tolerance to EAE.
The latest approach in animal models has been to
utilize glatiramer acetate (Cop1, Copaxone), a drug
approved for therapy of multiple sclerosis which is
given to patients by injection. Teitelbaum et al. (1999)
have found that oral glatiramer acetate suppresses
EAE in both the mouse and rat models and we
have found that oral glatiramer acetate suppresses
EAE in MBP T cell receptor transgenic animals and
induces the upregulation of TGF-b when given orally
(Maron et al. 2002b). Our working hypothesis is that
glatiramer acetate is acting as an altered peptide ligand
and is immunologically active in the gut (Weiner
1999).
Arthritis models
There are several animal models of arthritis including
collagen induced arthritis (CIA), adjuvant arthritis
(AA), pristane induced arthritis (PIA), antigen-
induced arthritis (AIA), silicone induced arthritis
and streptococcal cell with arthritis.
Immunization with heterologous or homologous
species of CII produces autoimmune responses to CII
that lead to development of arthritis in susceptible
mouse strains (Courtenay et al. 1980). CIA has been
used as an animal model for RA and is characterized
by chronic inﬂammation within the joints, associated
with synovitis and erosion of cartilage and bone
(Trentham et al. 1977). The ﬁrst experiments of oral
tolerance using rat CIA was done by Thompson and
Staines (1986) and Nagler-Anderson et al. (1986)
in WA/KIR rats and DBA/1 mice, respectively by
Table IV. Experimental models of autoimmune diseases sup-
pressed by oral tolerance.
Model Protein fed
EAE MBP, PLP, MOG,
copaxone
Arthritis (CIA, AA, AIA, PIA, SCW) Collagen II, Hsp65, BSA
Diabetes (NOD mouse) Insulin, insulin b-chain,
GAD, OVA
Colitis Haptenized or normal
colonic proteins, OVA
EAU S-Ag, IRBP
EAMG AchR
Anti-phospholipid syndrome b2-Glycoprotein
Experimental allergic neuritis PNS-myelin
Thyroiditis Thyroglobulin
Atherosclerosis Hsp65
Stroke MOG
Nerve injury MBP
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incomplete Freund’s adjuvant (CFA). Feeding of
CII prior to immunization delayed the onset and
suppressed the incidence of CIA.
Collagen peptides are also capable of inducing CIA.
Immunodominant collagen peptides have been used
to suppress CIA by oral administration. Khare et al.
(1995) induced CIA to DBA/1 mice by immunizing
with human CII peptide (250–270) in CFA. Oral
tolerance with human peptide CII (250–270)
abolished anti-human and anti-mouse CII Ab and
markedly reduced the disease severity both at early
and effector phases.
Another major model for RA is AA, which is a well-
characterized and fulminant form of experimental
arthritis. Oral administration of chicken CII consis-
tently suppressed the development of AA in Lewis
rats and the suppression of AA could be adoptively
transferred by T cells from CII fed animals (Zhang
et al. 1990b).
HSP plays an important role in the AA model (van
Eden et al. 1988). It was recently reported that oral
administration of mycobacterial 65-kDa HSP sup-
pressed the development of AA in rats (Haque et al.
1996). Suppression of AA was adoptive transferred by
spleen cells from orally tolerized rats.
Oral tolerance is also effective in PIA (Thompson
et al. 1993). Immunizing mice twice with 2, 6, 10,
14-tetramethylpentadecane (pristane) twice leads to
arthritisafter100 , 200days.Increasingdosesoforal
CII lowered both the incidence and severity of PIA.
Other animal models of arthritis that have been
successfully treated by mucosal tolerance include
streptococcal cell wall arthritis (Chen et al. 1998) and
silicone induced arthritis (Yoshino 1995).
Methotrexate is a widely used drug in RA. We
found that there is a synergistic effect between
methotrexate and orally administered Ag such as
MBP (al-Sabbagh et al. 1997) and a synergistic effect
with oral methotrexate was also observed in the AA
model (Weiner and Komagata 1998).
Diabetes
Oral insulin has been shown to delay and in some
instances, prevent diabetes in the NOD mouse model.
Such suppression is transferable (Zhang et al. 1991),
primarily with CD4
þ cells (Bergerot et al. 1999).
Immunohistochemistry of pancreatic islets of Langer-
hans isolated from insulin fed animals demonstrates
decreased insulitis (Hancock et al. 1995). Oral insulin
suppressed diabetes in a viral induced model of
diabetes in which LCMV was expressed under the
insulin promoter and animals infected with LCMV to
induce diabetes (von Herrath et al. 1996). Protection
was associated with protective cytokine shifts
(IL-4/IL-10, TGF-b) in the islets. It has also been
shown that expression of TGF-b in the pancreatic
islets protects the NOD mouse from diabetes (King
et al. 1998). Oral administration of b-chain of insulin,
a 30-amino-acid peptide slowed the development of
diabetes and prevented diabetes in some animals
(Polanski et al. 1997). This effect was associated with
a decrease IFN-g and an increase in IL-4, TGF-b and
IL-10 expression. Oral dosing of bacterial stimulants
such as LPS and E. Coli extract OM-89 in NOD mice
induces a Th2 shift in the gut cytokine gene expression
and concomitantly, improves diabetes prevention by
oral insulin administration (Bellmann et al. 1997).
Oral administration of recombinant GAD from
plant sources suppressed the development of diabetes
in NOD mouse as does oral administration of a plant-
based CTB-insulin fusion protein (Arakawa et al.
1998).
Colitis
TGF-b appears to play a crucial role in the
development of animal models of colitis, including
TNBS-colitis, colitis in the IL-2-deﬁcient animal
model following systemic administration of TNP-
KLH in adjuvant and in the model of Th1 colitis in
SCID mice. It has been shown that TNBS colitis can
be prevented by oral administration of TNBS, which
acts via the induction of TNBS-speciﬁc TGF-b
responses (Neurath et al. 1996). TNBS-induced
colitis in rats can also be prevented by feeding either
human colon epithelial cells or rat colonic epithelial
extracts, but not human ﬁbroblasts nor rat small
intestine extracts, showing that tolerance is organ
speciﬁc. Protected animals had low IFN-g and high
TGF-b levels and tolerance could be transferred by
mesenteric lymph nodes cells (Dasgupta et al. 2001).
In addition, colitis can be suppressed via bystander
suppression by transfer of OVA transgenic CD4þ-
CD45
high T cells (from DO.11.10 mice) into SCID
mice (Zhou et al. 2004).
Uveitis
Oral administration of S-Ag, a retinal autoantigen that
induces EAU, or S-Ag peptides prevents or markedly
diminishes the clinical appearance of S-Ag-induced
disease as measured by ocular inﬂammation (Nussen-
blatt et al. 1990). S-Ag-induced EAU can also be
suppressed by feeding an HLA peptide (Wildner and
Thurau 1994). Feeding interphotoreceptor binding
protein (IRBP) suppresses IRBP-induced disease and
is potentiated by IL-2 (Rizzo et al. 1994). Oral feeding
of retinal Ag not only can prevent acute disease but
also can effectively suppress second attack in chronic-
relapsing EAU, demonstrating that oral tolerance may
have practical clinical implications in uveitis, which
is predominantly a chronic-relapsing condition in
humans (Thurau et al. 1997a,b). Other investigators
have found that oral administration of bovine S-Ag
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only inhibit mild disease if feeding was delayed until
after immunization and relatively high feeding doses
were required (Ma et al. 1998; Torseth and Gregerson
1998).
Myasthenia
Although myasthenia gravis is an Ab-mediated
disease, oral administration of the Torpedo acetyl-
choline receptor (AchR) to Lewis rats prevented or
delayed the onset of myasthenia gravis. The levels of
anti-AchR antibodies in the serum were lower in orally
tolerized animals than in control animals. The effect
was dose dependent and large doses of Ag (at least
5mg of AchR) plus soybean tripsin inhibitor (STI)
(Wang et al. 1993) were required, suggesting that
anergy may be the primary mechanism. Puriﬁed AchR
was found more effective than an unpuriﬁed mixture
(Okumura et al. 1994).
Other autoimmune diseases
The antiphospholipid syndrome is characterized by
the presence of high titers of IgG anticardiolipin
antibodies and/or lupus anticoagulant antibodies.Oral
administration in BALB/c mice of low doses of b2
glycoprotein prevented the serologic and clinical
manifestation of experimental antiphospholipid
syndrome upon immunization with the autoantigen.
Decreased T cell responses, Ab responses and
increased expression of TGF-b which mediated the
suppression was demonstrated. Tolerance was trans-
ferred by CD8 positive class I restricted TGF-b
secreting cells (Blank et al. 1998).
Immune complex disease can be suppressed both
following administration of a single large dose of Ag
(Browning and Parrott 1987) or by placing Ag in
drinking water (Devey and Bleasdale 1984). These
studies were performed before oral tolerance was
applied to autoimmune diseases. It has also been
raised whether defective oral tolerance may be
associated with experimental IgA nephropathy
(Gesualdo et al. 1990). A recent report shows that
feeding of Ro 274 peptide or Ro 60 to BALB/c mice
with Sjogren’s syndrome-like disease (immunized
with Ro 60 previously) drastically reduces salivary
inﬁltrates and speciﬁc Ab production (Kurien et al.
2005).
Thyroiditis has been effectively suppressed follow-
ing oral administration of either porcine or human
thyroglobulin (Guimara ˜es et al. 1995; Peterson and
Braley-Mullen 1995). In the murine model, CD8
positive regulatory cells which produce IL-4 and
TGF-b mediated the suppression (Guimaraes et al.
1995). These cells also appear to induce bystander
suppression upon triggering with the fed Ag.
Other investigators (Zhang and Kong 1998) reported
that tolerance induced by IV administration of
deaggregated thyroglobulin in experimental auto-
immune thyroiditis (EAT) is dependent on CD4þ
T cells but independent of IL-4/IL-10.
Experimental allergic neuritis is the counterpart of
EAE and can be suppressed both by oral adminis-
tration of peripheral nerve proteins (Gaupp et al.
1997).
Link’s group has experimented with administering
Ag associated with more than one autoimmune
disease and immunizing with a mixture of Ag. They
have demonstrated that oral administration of AChR
plus MBP suppresses EAMG and EAE (Wang et al.
1995). Thus, it appears there is no interference by one
autoantigen versus another when they are from
different target organs.
Treatment of autoimmune diseases in humans
using oral tolerance (Table V)
Based on the long history of oral tolerance and the
safety of the approach, human trials have been
initiated in autoimmune diseases, MS, RA, uveitis
and diabetes. These initial trials suggest that there has
been no systemic toxicity or exacerbation of disease,
although clinical efﬁcacy resulting in an approved
drug has yet been demonstrated. Results in humans
however, have paralleled several aspects of what has
been observed in animals.
Table V. Human studies of oral tolerance application in
autoimmune diseases.
A. Diabetes
Preliminary report: Preservedbeta-cellfunctionas measuredby
endogenous C-peptide in new onset diabetics over 20 years old
fed 1mg;
Oral insulin not beneﬁcial in new onset disease fed 2.5 or
7.5mg oral insulin for 1 year;
B. Multiple sclerosis
Oral myelin decreased MRI lesions in DR2 þ males, no effect
on clinical relapse;
Increased TGF-b secreting myelin cells after oral myelin;
C. RA
Oral collagen ameliorates RA;
Oral collagen beneﬁts juvenile RA in open label trial;
20mg best in double blind oral dosing trial of CII;
Oral bovine collagen at higher doses without positive effect;
60mg oral collagen best in composite analysis of dosing trials;
no different than placebo in phase III trial;
Bovine collagen (0.5mg) beneﬁcial in placebo controlled trial;
Oral collagen II beneﬁcial in JRA clinically and immunologi-
cally in pilot trial;
D. Uveitis
Oral S-Ag appeared to allow medication taper, retinal mixture
appeared to worsen uveitis;
Oral HLA peptide allowed steroid taper;
E. Thyroid disease
Decreased cellular immunity to thyroglobulin in patients
receiving oral thyroglobulin
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Six different trials are currently underway or
completed in testing mucosally administered recom-
binant human insulin as a tolerizing agent in type 1
diabetes: (1) a multicenter double-blind study in the
US evaluating oral insulin therapy versus placebo in
adults and children with new-onset disease. Prelimi-
nary analysis suggests preserved beta cell function as
measured by endogenous C-peptide insulin responses
in patients diagnosed over age 20 years and fed 1mg.
versus placebo (Ergun-Longmire et al. 2004); (2) a
double-blind study in France to compare oral insulin
therapy and parenteral insulin therapy versus placebo
in patients during the remission phase. Evaluation
criteria include duration of remission, measures of
insulin secretion/sensitivity and immunological par-
ameters; no effect of treatment with 2.5 or 7.5mg oral
insulin was observed (Chaillous et al. 2000); (3) a
multicenter double-blind study in Italy to evaluate
whether the addition of oral insulin is able to improve
the integrated parameters of metabolic control and
modify immunological ﬁndings compared to placebo
in patients with recent onset disease treated with
intensive insulin therapy (IMDIAB VI). No effect
of subcutaneous insulin was observed but a positive
effect of 7.5mg of oral insulin in a high risk cohort was
observed and a repeat trial of 7.5mg of oral insulin
is being planned at patients at risk. (Skyler, J., Oral
communication. Immunology of Diabetes Society
Meeting, Cambridge, England, 2004); (4) a multi-
center double-blind study in the US to determine if
diabetes can be prevented by subcutaneous insulin
therapy or oral insulin therapy in subjects at risk
for diabetes (DPT-1); (5) a double-blind study in
Australia evaluating aerosolized insulin versus placebo
in patients with new-onset disease; and (6) a double-
blind study in Finland evaluating nasally administered
insulin versus placebo in patients with new-onset
disease. A recent report shows that oral insulin
treatment of patients with type 1 diabetes for 12
months was able to deviate the pattern of response of
their peripheral mononuclear cells towards an
increased production of TGF-b (Monetini et al.
2004).
Multiple sclerosis
In MS patients, MBP- and PLP-speciﬁc TGF-b-
secreting Th3-type cells have been observed in the
peripheral blood of patients treated with an oral
bovine myelin preparation and not in patients who
were untreated (Fukaura et al. 1996). These results
demonstrate that it is possible to immunize via the gut
for autoantigen-speciﬁc TGF-b-secreting cells in a
human autoimmune disease by oral administration of
the autoantigen. However, a completed 515 patient,
placebo-controlled, double-blind phase III trial of
single-dose bovine myelin in relapsing-remitting MS
did not show differences between placebo and treated
groups in the number ofrelapses; a large placebo effect
was observed (AutoImmune Inc., Lexington, MA,
USA). The dose of myelin was 300mg given in
capsule form and contained 8mg MBP and 15mg
PLP. Preliminary analysis of magnetic resonance
imaging data showed signiﬁcant changes favoring
oral myelin in certain patient subgroups. Trials in MS
have been undertaken with the MBP analogue,
glatiramer acetate, which is currently given by
injection to MS patients but has been shown to be
effective orally in animals and to induce regulatory
cells that mediate bystander suppression (Teitelbaum
et al. 1999; Weiner 1999). A phase III trial of oral
glatiramer acetate given daily at 5 and 50mg versus
placebo found no clinical, MRI, or immunologic
effects. Phase II trials testing oral GA at doses of 300
and 600mg are currently in progress.
Rheumatoid arthritis
In RA, a 280 patient double-blind phase II dosing trial
of CII in liquid doses ranging from 20 to 2500mgp e r
day for six months demonstrated statistically signiﬁ-
cant positive effects in the group treated with the
lowest dose (Barnett and Kremer 1998). Oral
administration of larger doses of bovine CII (1–
10mg) did not show a signiﬁcant difference between
tested and placebo groups, although a higher
prevalence of responders was reported for the groups
treated with CII. These results are consistent with
animal studies of orally administered CII in which
protection against adjuvant- and Ag-induced arthritis
and bystander suppression was observed only at the
lower doses (Zhang et al. 1990b; Yoshino 1995). An
open-label pilot study of oral collagen in juvenile RA
gave positive results with no toxicity (Barnett et al.
1996). This lack of systemic toxicity is an important
feature for the clinical use of oral tolerance, especially
in children for whom the long-term effects of
immunosuppressive drugs is unknown.
Five phase II randomized studies of oral CII have
been performed and based on the results obtained, a
multicenter double-blind phase III trial study of oral
CII (Colloralw) was undertaken (AutoImmune Inc.).
In the ﬁve double-blind phase II studies a total of 805
patients were treated with oral CII and 296 treated
with placebo. Two of the studies have been published
(Trentham et al. 1993; Barnett et al. 1998). The other
three studies were included in a integrated analysis
that led to the decision to carry out a phase III trial. A
dose reﬁnement study tested doses of 5, 20 and 60mg.
Colloral at 60mg was found to be the most signiﬁcant
dose compared to other doses. Safety analysis
demonstrated that Colloral was extraordinarily safe
with no side effects. The magnitude of the clinical
responses of Colloral appears to be on the same level
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there is a sub-group of patients that appear to have a
more signiﬁcant response to the medication. Based on
these data, a 760-patient phase III trial was performed
comparing 60mg of Colloral to placebo. However, no
differences were observed. There was a large placebo
effect in the control group. Subsequently, a placebo
controlled trial of bovine collagen showed signiﬁcant
effects in those receiving 0.5mg, but not in groups
receiving 0.05 or 5mg (Choy et al. 2001). Oral CII in
juvenile RA was associated with clinical improvement
and decreased CII speciﬁc IFN-g and increased
TGF-b (Myers et al. 2001). Clinical trials are
underway to determine whether withholding NSAIDS
and prednisone will allow OT to be induced and
whether oral CII has meaningful clinical efﬁcacy in RA
(Postlethwaite 2001).
Uveitis
In uveitis, a pilot trial of S-Ag and an S-Ag mixture
was conducted at the National Eye Institute
(Bethesda, MD, USA) and showed positive trends
with oral bovine S-Ag but not the retinal mixture
(Nussenblatt et al. 1997). Feeding of peptide derived
from patient’s own HLA Ag appeared to have effect on
uveitis in that patients could discontinue their steroids
because of reduced intraocular inﬂammation
mediated by oral tolerance (Thurau et al. 1997b).
Thyroid
Thirteen patients receiving thyroid hormone replace-
ment with synthetic thyroxin were randomly assigned
to receive oral porcine thyroid or remain on synthetic
T4 (Lee et al. 1998). Humoral and cellular immune
responses were measured over the course of a year.
A decrease in cellular immunity to thyroid peptides
was observed in the fed versus the control group. No
changes between groups were observed in autoanti-
body levels.
Other
Positive effects were reported in an open label pilot
study of oral type I collagen in patients with systemic
sclerosis (McKown et al. 1997, 2000).
Future directions
In spite of the negative results to date of phase III
human trials of mucosal tolerance, many lessons have
been learned from them as well as from the sucessful
experiments with animal models. Based on the results
of oral tolerance in uveitis in humans (Nussenblatt
et al. 1997) and in animal models of myasthenia
(Okumura et al. 1994) and EAE (Benson et al. 1999),
it appears that protein mixtures may not be as effective
oral tolerogens as puriﬁed proteins.
Although it is clear that oral Ag can suppress
autoimmunity and inﬂammatory diseases in animals,
it is now clear from all these studies that several factors
need to be carefully considered to improve the
effectiveness of oral tolerance in human disease: (1)
the dose of Ag is crucial; (2) a clear immunological
marker or immunological effect has to be established
as a parameter for the follow-up of each disease; (3)
some mucosal adjuvants that enhance induction of
mucosal have been described and may need to be
used; (4) puriﬁed proteins are more effective oral
tolerogens than protein mixtures; (5) frequency of oral
administration interferes with efﬁciency of suppres-
sion achieved; (6) combination therapy using conven-
tional anti-inﬂammatory and immunosuppressive
drugs may yield a better result; and (7) early therapy
is an important factor since oral tolerance is mostly
effective before or shortly after disease onset.
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